StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $2.14 | $2.25 | +5.14% | 0.1M |
| 05-12 | $2.23 | $2.27 | +1.79% | 0.1M |
| 05-13 | $2.29 | $2.31 | +0.87% | 0.3M |
| 05-14 | $2.24 | $2.59 | +15.62% | 0.5M |
| 05-15 | $2.58 | $2.18 | -15.50% | 0.5M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 | Q1 2024 2024-03-31 |
|---|---|---|---|---|
Revenue | $41.09M | $36.70M | $24.54M | $10.69M |
Operating Income | $-8.27M | $-3.57M | $-2.89M | $-2.79M |
Net Income | $-8.07M | $-2.27M | $468.00K | $-2.73M |
EPS (Diluted) | $-0.23 | $-0.06 | $-0.06 | $-0.08 |
Total Assets | $25.60M | $34.46M | $42.86M | $43.60M |
Total Liabilities | $6.54M | $11.28M | $20.43M | $22.50M |
Cash & Equivalents | $18.09M | $15.45M | $11.06M | $11.57M |
Free Cash Flow OCF − CapEx | $-19.11M | $-15.81M | $-8.15M | $-8.82M |
Shares Outstanding | 35.56M | 35.42M | 35.42M | 35.25M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.